| Integrated proteogenomic characterization of clear cell renal cell carcinoma DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ... Cell 179 (4), 964-983. e31, 2019 | 594 | 2019 |
| Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 379 | 2020 |
| Co-evolution of tumor and immune cells during progression of multiple myeloma R Liu, Q Gao, SM Foltz, JS Fowles, L Yao, JT Wang, S Cao, H Sun, ... Nature communications 12 (1), 2559, 2021 | 112 | 2021 |
| Modified cross-linking, ligation, and sequencing of hybrids (qCLASH) identifies Kaposi's sarcoma-associated herpesvirus microRNA targets in endothelial cells LA Gay, S Sethuraman, M Thomas, PC Turner, R Renne Journal of virology 92 (8), 10.1128/jvi. 02138-17, 2018 | 55 | 2018 |
| Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin WW Liang, RJH Lu, RG Jayasinghe, SM Foltz, E Porta-Pardo, Y Geffen, ... Cancer cell 41 (9), 1567-1585. e7, 2023 | 35 | 2023 |
| microRNA dependent and independent deregulation of long non-coding RNAs by an oncogenic herpesvirus S Sethuraman, LA Gay, V Jain, I Haecker, R Renne PLoS pathogens 13 (7), e1006508, 2017 | 32 | 2017 |
| VISTA is an activating receptor in human monocytes BM Rogers, L Smith, Z Dezso, X Shi, E DiGiammarino, D Nguyen, ... Journal of Experimental Medicine 218 (8), e20201601, 2021 | 30 | 2021 |
| Identification of murine gammaherpesvirus 68 miRNA-mRNA hybrids reveals miRNA target conservation among gammaherpesviruses including host translation and protein modification … WL Bullard, M Kara, LA Gay, S Sethuraman, Y Wang, S Nirmalan, ... PLoS Pathogens 15 (8), e1007843, 2019 | 26 | 2019 |
| Computational analysis of ribonomics datasets identifies long non-coding RNA targets of γ-herpesviral miRNAs S Sethuraman, M Thomas, LA Gay, R Renne Nucleic Acids Research 46 (16), 8574-8589, 2018 | 26 | 2018 |
| Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid … TA Yap, A Schram, EK Lee, F Simpkins, MC Weiss, P LoRusso, ... Molecular Cancer Therapeutics 22 (12_Supplement), PR008-PR008, 2023 | 5 | 2023 |
| 504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study) ZA Wainberg, AH Bent, V Moreno, M Pedregal, R Mehta, EX Chen, ... Annals of Oncology 35, S201, 2024 | 1 | 2024 |
| MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 … TA Yap, A Schram, EK Lee, F Simpkins, MC Weiss, P LoRusso, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | 1 | 2023 |
| Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers S Sethuraman, D Glodzik, P Selenica, A Johnson, JS Reis-Filho, A Veloso, ... Cancer Research 83 (7_Supplement), 5469-5469, 2023 | 1 | 2023 |
| 57 (PB045): Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib … M Hojgaard, TA Yap, EK Lee, MC Weiss, S Lheureux, F Simpkins, ... European Journal of Cancer 211, 114584, 2024 | | 2024 |
| Treatment resistance to melanoma therapeutics on a single cell level L Yao, BA Krasnick, Y Bi, S Sethuraman, S Goedegebuure, ... Scientific reports 14 (1), 21915, 2024 | | 2024 |
| Abstract A017: Characterizing intratumoral heterogeneity of CCNE1 amplification in ovarian cancer using digital pathology A Petrone, I Soria-Bretones, A Johnson, S Sethuraman, IM Silverman, ... Molecular Cancer Therapeutics 23 (6_Supplement), A017-A017, 2024 | | 2024 |
| Comprehensive baseline ctDNA characterization in two biomarker-selected Phase 1/2 studies using genomic and methylation profiling IM Silverman, JD Schonhoft, B Herzberg, A Yablonovitch, E Lagow, ... medRxiv, 2024.11. 11.24316049, 2024 | | 2024 |
| Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 … E Aguado-Fraile, S Sethuraman, A Petrone, E Bacque, A Schram, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors … E Aguado-Fraile, S Sethuraman, A Petrone, E Bacque, A Schram, ... Molecular Cancer Therapeutics 22 (12_Supplement), B169-B169, 2023 | | 2023 |
| Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response … E Rosen, JD Schonhoft, IM Silverman, A Yablonovitch, S Sethuraman, ... Molecular Cancer Therapeutics 22 (12_Supplement), A123-A123, 2023 | | 2023 |
Rolf RenneUniversity of Florida在 ufl.edu 的电子邮件经过验证
